
| Image Class: | skin-invert-image |
| Width: | 150 |
| Tradename: | Nereus |
| Dailymedid: | Tradipitant |
| Routes Of Administration: | By mouth |
| Class: | Neurokinin NK1 antagonist |
| Atc Prefix: | None |
| Legal Us: | Rx-only |
| Legal Us Comment: | [1] |
| Cas Number: | 622370-35-8 |
| Pubchem: | 9916461 |
| Drugbank: | DB12580 |
| Chemspiderid: | 8092108 |
| Unii: | NY0COC51FI |
| Kegg: | D11728 |
| Chembl: | 3544984 |
| Synonyms: | VLY-686, LY686017 |
| Iupac Name: | (2-(1-(3,5-Bis(trifluoromethyl)benzyl)-5-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)(2-chlorophenyl)methanone |
| C: | 28 |
| H: | 16 |
| Cl: | 1 |
| F: | 6 |
| N: | 5 |
| O: | 1 |
| Smiles: | Clc1ccccc1C(=O)c2c(nccc2)c3nnn(c3c4ccncc4)Cc5cc(cc(c5)C(F)(F)F)C(F)(F)F |
| Stdinchi: | 1S/C28H16ClF6N5O/c29-22-6-2-1-4-20(22)26(41)21-5-3-9-37-23(21)24-25(17-7-10-36-11-8-17)40(39-38-24)15-16-12-18(27(30,31)32)14-19(13-16)28(33,34)35/h1-14H,15H2 |
| Stdinchikey: | CAVRKWRKTNINFF-UHFFFAOYSA-N |
Tradipitant, sold under the brand name Nereus, is a medication used as prevention of vomiting induced by motion (motion sickness). It is a neurokinin 1 receptor antagonist. It works by blocking substance P, a small signaling molecule. VLY-686 was purchased by Vanda Pharmaceuticals from Eli Lilly and Company in 2012.[2]
Tradipitant was approved for medical use in the United States in December 2025.[3]
Tradipitant is indicated for the prevention of vomiting induced by motion.
Tradipitant was approved for medical use in the United States in December 2025.[4]
Tradipitant is the international nonproprietary name.[5]
Tradipitant is sold under the brand name Nereus.